-+ 0.00%
-+ 0.00%
-+ 0.00%
Zhitong Finance App News, Junshi Biotech (01877.HK) issued an announcement. Recently, Shanghai Junshi Biomedical Technology Co., Ltd. (hereinafter referred to as the “Company”) product treprilizumab injection (trade name: Tuoyi®, product code: JS001) combined with viducitumab for locally advanced or metastatic urothelial carcinoma expressed by HER2 was successfully included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2026)” (hereinafter referred to as the “National Health Insurance Catalogue”). The new version of the National Health Insurance Catalogue will be officially implemented on January 1, 2027.
Share
Listen to the news
Zhitong Finance App News, Junshi Biotech (01877.HK) issued an announcement. Recently, Shanghai Junshi Biomedical Technology Co., Ltd. (hereinafter referred to as the “Company”) product treprilizumab injection (trade name: Tuoyi®, product code: JS001) combined with viducitumab for locally advanced or metastatic urothelial carcinoma expressed by HER2 was successfully included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2026)” (hereinafter referred to as the “National Health Insurance Catalogue”). The new version of the National Health Insurance Catalogue will be officially implemented on January 1, 2027.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending